markusathome

[markusathome @MarkusAtHome]

Caplacizumab for PE-free TTP Treatment - MAYARI - Prof. Paul Coppo, Prof. Paul Brinkkötter

https://t.co/tdkYR3anPo

[markusathome @MarkusAtHome]

Anticoagulation in CKD & A Fib - SACK - Dr. Marie Evans, Dr. Anne-Laure Faucon (Stockholm, Sweden)

https://t.co/W23z3AmceL

[markusathome @MarkusAtHome]

Flu / RSV Vaccination: DANFLU-2 / DAN-RSV / VHA - Prof. K. Bajema, @TorBiering

https://t.co/zegb5eC28n

[markusathome @MarkusAtHome]

We are very pleased to welcome him back:

Lipidologie für Nichtlipidologen I: LDL-C - Prof. Dr. Ulrich Laufs (Leipzig)

https://t.co/JMYwFd7gKl

[markusathome @MarkusAtHome]

Finally, the time has come: Nephrology / Hypertension 2025 II

...simultaneously with our 6000th follower!

Who will be on the winner's podium?

https://t.co/HJBOLBYmpW

[markusathome @MarkusAtHome]

Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a) by Drs. Nordestgaard, Ridker et al.

Very high Lp(a) levels correlated with increased 30-year risk of CV disease among healthy women.

https://t.co/VA5sdON4G9

[markusathome @MarkusAtHome]

Age-Adjusted D-Dimer Cutoff Levels to Rule Out Deep Vein Thrombosis by Drs. Le Gal, Righini et al.

The age-adjusted D-dimer cutoff may safely rule out DVT and was associated with a larger number of patients in whom DVT could be effectively ruled out.

https://t.co/lI94J7IdUj

[markusathome @MarkusAtHome]

It's that time again!

Nephrology/Hypertension – Top Studies 2025, Part 1!

https://t.co/DDK2DLJVyY

@gunnar_heine @AKronbichler @MarcusSaemann

[markusathome @MarkusAtHome]

The MARKUS@HOMe editorial team wishes all colleagues a happy New Year's Eve 2025 and a happy, healthy, peaceful, and safe 2026.

We thank all our guests for their academic contributions and look forward to seeing you again in 2026!

https://t.co/QZshSjKUrh

[markusathome @MarkusAtHome]

Our top-rated cardiology study of 2025 (Best of cardiology)

Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction by Drs. Bavendiek, @JBauersachsMD et al.

https://t.co/kMoalbQbcP

[markusathome @MarkusAtHome]

In our special Christmas episode, Mr. Reinhard Ernst (Wiesbaden) discusses the importance of access to abstract art in general and to abstract expressionism in painting in particular for people in Germany in 2026

https://t.co/KlMQzJo1dk

[markusathome @MarkusAtHome]

The MARKUS@HOME editorial team wishes all colleagues a peaceful and blessed Christmas 2025.

Thank you for your interest in our webinars. We look forward to seeing you again in 2026!

https://t.co/PlajsaSEWJ

[markusathome @MarkusAtHome]

Short-Term DOAC vs. DAPT for Preventing Device Thrombosis Following LAA-Closure: The ANDES RCT by Drs. Rodés-Cabau, Salaun et al.

https://t.co/fh27TdLtF6

The use of DOACs after LAAC failed to reduce DRT compared with DAPT, but it was associated with an improved safety profile.

[markusathome @MarkusAtHome]

It's that time again: Best of Cardiologie 2025

https://t.co/jxIZ5lZoJg

Watch now!

[markusathome @MarkusAtHome]

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes by Drs. @ProfSNicholls, D’Alessio et al.

https://t.co/Nd9yzuvx5Y

Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide.

[markusathome @MarkusAtHome]

Exercise and Kidney Health: Core Curriculum 2026 by Drs. @LauraAponteBe, @renalgal.

https://t.co/OCyCiwsGQQ

This core curriculum reviews the physiology of exercise on kidney function and provides evidence-based strategies for patient counseling and risk reduction.

[markusathome @MarkusAtHome]

Update AF: DECAF & CABG-AF

@gregorymmarcus
& Florian Herrmann

https://t.co/1Q4vbbEtDN

[markusathome @MarkusAtHome]

Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis by Drs. van Essen, Tromp et al.

https://t.co/yIyUOXPyh8

[markusathome @MarkusAtHome]

Antithrombotic Therapy in ASCVD + VTE: AQUATIC - Prof. Behnood Bikdeli, Prof. Romain Didier

https://t.co/tl55cc228t

@bbikdeli

[markusathome @MarkusAtHome]

VALIANT: Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN by Drs. Fakhouri, Nester et al.
https://t.co/7hAAF7jMhf
Pegcetacoplan resulted in a significantly greater reduction in proteinuria than placebo among patients with C3 GN or primary immune-complex MPGN.